2405 Route Des Dolines
Drakkar 2 Bât D
Valbonne 06560
France
33 4 97 24 53 00
https://www.nicox.com
Sector(s):
Industry:
Full-time employees: 28
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. Sandrine Gestin | Vice President of Finance | N/A | N/A | 1967 |
Mr. Doug Hubatsch | Executive VP & Chief Scientific Officer | N/A | N/A | 1967 |
Dr. Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control | N/A | N/A | N/A |
Dr. Jose Boyer | Consultant | N/A | N/A | N/A |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
Nicox S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.